US Stock MarketDetailed Quotes
SXTP 60 Degrees Pharmaceuticals
- 0.828
- +0.003+0.31%
Close Jan 17 16:00 ET
- 0.785
- -0.043-5.16%
Post 20:01 ET
1.90MMarket Cap-0.26P/E (TTM)
0.860High0.770Low322.50KVolume0.798Open0.825Pre Close263.31KTurnover19.65%Turnover RatioLossP/E (Static)2.30MShares10.66852wk High-0.54P/B1.36MFloat Cap0.70252wk Low--Dividend TTM1.64MShs Float103.800Historical High--Div YieldTTM10.90%Amplitude0.701Historical Low0.816Avg Price1Lot Size
60 Degrees Pharmaceuticals Stock Forum
Sign in to post a comment
$60 Degrees Pharmaceuticals (SXTP.US)$ high volume but isn't worth a 💩. smh
1
1
$60 Degrees Pharmaceuticals (SXTP.US)$ Reuters· 3 mins ago
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. Microti) Babesiosis
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. Microti) Babesiosis
2
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, ...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, ...
64
25
13
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catal...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catal...
96
27
20
$60 Degrees Pharmaceuticals (SXTP.US)$
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
Monday, 23rd December at 8:57 am
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW)) ("60 Degrees" or the "Company"), pharmaceutical company, and Tufts Medical Center ("Tufts MC"), a leading academic medical center, today announced the signi...
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
Monday, 23rd December at 8:57 am
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW)) ("60 Degrees" or the "Company"), pharmaceutical company, and Tufts Medical Center ("Tufts MC"), a leading academic medical center, today announced the signi...
$60 Degrees Pharmaceuticals (SXTP.US)$
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
Wednesday, 11th December at 8:56 am
• The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.
• The clinical site is led by Brigham and Women's Hospital researchers Ann Woolley, M.D., and David Leaf, M.D.
• The double-blind, placebo-controlled trial will examine ou...
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
Wednesday, 11th December at 8:56 am
• The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.
• The clinical site is led by Brigham and Women's Hospital researchers Ann Woolley, M.D., and David Leaf, M.D.
• The double-blind, placebo-controlled trial will examine ou...
$60 Degrees Pharmaceuticals (SXTP.US)$
no matter how much it is rising now, many former traders of this stock have lost confidence in this stock because it had dropped more and more every day! when people were holding the shares and they bought at 1.5+ , it had decreased to 1, then 0.95, then it suddenly rised to 1.38 for a few seconds, most of the traders did not had the chance to sell their shares because it only last for a few seconds! then it dropped to about 1 again, then 0.9, then 0.8.5, an...
no matter how much it is rising now, many former traders of this stock have lost confidence in this stock because it had dropped more and more every day! when people were holding the shares and they bought at 1.5+ , it had decreased to 1, then 0.95, then it suddenly rised to 1.38 for a few seconds, most of the traders did not had the chance to sell their shares because it only last for a few seconds! then it dropped to about 1 again, then 0.9, then 0.8.5, an...
2
1
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
ProperMicheleV : u r 100% correct. Tanefoquine is not the answer to chronic babesiosis. However, this company is somehow connected to the CDC & important legislators in DC. Their HQ is located steps away from all the important pharma players in DC & the senate. That being said, at some point, after Yale, Tufts & NC college of Veterinary Medicine, publish the pps will
. We all know those academic institutions are paid to provide answers that benefit whose paying them, not only by corrupt grants but flat fees for their research. Long story short.... they have a dog in the fight. There should be laws against that. If I give 250k to Harvard Business Review, I can get a ham sandwich in pill form touted as the next "cure all". There is total catastrophic failure on the horizon. & I feel GSK is still involved with Tanefoquine aka Krintafel. Google it.